Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia
AIDSPublished 1 February 2000
Sabine Yerly, Laurent Kaiser, Thomas Perneger, Richard W. Cone, Milos Opravil, J. P. Chave
Citations86
SJR quartileQ1
SJR score1.21
SNIP0.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Viraemia levels are associated with clinical progression and predict virological treatment failure, and the initiation of antiretroviral therapy at the time of PHI and while CD4 cell counts are high results in lower residual viraemia.
Abstract
Viraemia levels are associated with clinical progression and predict virological treatment failure. The initiation of antiretroviral therapy at the time of PHI and while CD4 cell counts are high results in lower residual viraemia. These results support early antiretroviral therapy in HIV-1-infected patients.
Keywords
Immunology and MicrobiologyMedicine
BiometrikaLongitudinal data analysis using generalized linear models
18,123 Citations1986Kung‐Yee Liang, Scott L. Zeger
ScienceIdentification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
3,123 Citations1997Diana Finzi, Monika Hermankova +13 more
In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes, and generally did not show mutations associated with resistance to the relevant antiretroviral drugs.
SciencePrognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
2,705 Citations1996John W. Mellors, Charles R. Rinaldo +4 more
Plasma viral load was a better predictor of progression to AIDS and death than was the number of CD4+ T cells, and the risk of acquired immunodeficiency syndrome (AIDS) and death in study subjects was directly related to plasma viral load at study entry.
New England Journal of MedicineA Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
2,666 Citations1997Scott M. Hammer, Kathleen Squires +14 more
Treatment with indinavir, zidovudine, and lamivudine as compared with zidvudine and lam ivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidavudine.
ScienceRecovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia
2,227 Citations1997Joseph K. Wong, Marjan Hezareh +5 more
Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.
Nature MedicineLatent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
2,141 Citations1999Diana Finzi, Joel N. Blankson +15 more
Journal of the American Statistical AssociationRobust Locally Weighted Regression and Smoothing Scatterplots
2,056 Citations1979William S. Cleveland
ScienceHIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
1,985 Citations1995John M. Coffin
Results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual.
New England Journal of MedicineTreatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
1,900 Citations1997Roy M. Gulick, John W. Mellors +14 more
In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year.
ScienceVigorous HIV-1-Specific CD4 <sup>+</sup> T Cell Responses Associated with Control of Viremia
1,842 Citations1997Eric Rosenberg, James M. Billingsley +5 more
In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4+ T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines.
New England Journal of MedicineQuantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
823 Citations1999Linqi Zhang, Bharat Ramratnam +16 more
It is suggested that combination antiretroviral regimens suppress HIV-1 replication in some but not all patients, and given the half-life of latently infected CD4 lymphocytes of about six months, it may require many years of effective antireTroviral treatment to eliminate this reservoir of HIV- 1.
JAMAEffectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration
748 Citations1998Roger Detels
In the calendar period when potent antiretroviral therapy was introduced, the time to development of AIDS and time to death were extended, and rate of CD4 cell count decline was arrested.
ScienceKinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection
630 Citations1997Winston Cavert, Daan W. Notermans +11 more
In lymphoid tissue, where human immunodeficiency virus-type 1 (HIV-1) is produced and stored, three-drug treatment with viral protease and reverse transcriptase inhibitors markedly reduced viral burden and cleared >99.9 percent of virus from the secondary lymphoids tissue reservoir.
The LancetRandomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
540 Citations1998D. William Cameron, Margo Heath‐Chiozzi +9 more
Although earlier intervention with combination therapy may provide much more effective treatment, ritonavir in patients with advanced disease and extensive previous antiretroviral use is safe and effective, lowers the risk of AIDS complications, and prolongs survival.
Annals of Internal MedicineImmunopathogenic Mechanisms of HIV Infection
507 Citations1996Anthony S. Fauci, Giuseppe Pantaleo +2 more
The mechanisms operable in an appropriate immune response to HIV, particularly activation of the immune system, are paradoxically the same mechanisms that propagate HIV infection and lead to the ultimate destruction of lymphoid tissue and to profound immunosuppression.
New England Journal of MedicineTime to Hit HIV, Early and Hard
431 Citations1995David D. Ho
Early treatment of asymptomatic human immunodeficiency virus type 1 (HIV-1) infection remains controversial.
The Journal of Experimental MedicineQuantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.
423 Citations1993A.J. Carmichael, Xia Jin +2 more
CTL precursors were detected against all three HIV-1 structural gene products in patients with CD4+ lymphocyte counts > 400/microliters, at frequencies that are high compared with those reported for other persistent viruses.
AIDSAstrocytes: HIV cellular reservoirs and important participants in neuropathogenesis
318 Citations1999Ruth Brack‐Werner
The cellular basis and mechanisms underlying HIV-1 neuropathogenesis are complex and poorly understood and Astrocytes are the most abundant cell type in the central nervous system.
New England Journal of MedicineA Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection
313 Citations1995Sabine Kinloch de Loes, Bernard Hirschel +18 more
Antiretroviral therapy administered during primary HIV infection may improve the subsequent clinical course and increase the CD4 cell count.
AIDSSuppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
259 Citations1998Janet Raboud, Joan Montaner +11 more
The results demonstrate that suppression of pVL below 20 copies/ml is necessary to achieve a long-term antiretroviral response and support the need for a revision of current therapeutic guidelines for the management of HIV infection.
AIDSThe duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
224 Citations1998Dale J. Kempf, Richard A. Rode +9 more
Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy and strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response should be investigated.
The Journal of Experimental MedicineConstant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA
218 Citations1999Richard D. Hockett, J Michael Kilby +8 more
A novel strategy for the coordinated analysis of virus expression in lymph node specimens is reported, suggesting that fully replication-active cells are responsible for sustaining viremia after initiation of potent antiretroviral therapy and that plasma virus titers correlate, albeit in a nonlinear fashion, with the number of virus-expressing cells in lymphoid tissue.
The Journal of Infectious DiseasesIn Vitro T Cell Function, Delayed-Type Hypersensitivity Skin Testing, and CD4+ T Cell Subset Phenotyping Independently Predict Survival Time in Patients Infected with Human Immunodeficiency Virus
149 Citations1995Matthew J. Dolan, Mario Clerici +8 more
Cellular immune functional tests have significant predictive value for survival time in HIV-1-infected patients independent of CD4+ cell count.
Nature MedicineEvolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy
134 Citations1998Giuseppe Pantaleo, Oren J. Cohen +10 more
During the transition from primary to chronic HIV infection, the level of HIV replication in lymphoid tissue remains elevated despite the fact that viremia is significantly downregulated, having implications for therapeutic strategies in primary HIV infection and in recent seroconvertors.
AIDSHighly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities
106 Citations1998Leslie R. Bisset, Richard W. Cone +6 more
The observed ability of HAART during early asymptomatic HIV infection to initiate rapid reversal of disease-induced T-cell activation and maturation abnormalities, while preserving pretherapy levels of immune function, supports the concept that therapeutic advantage is to be gained by commencing early aggressive antiretroviral therapy.
Archives of Internal MedicineA Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4+ Cell Counts in HIV-Infected Patients
68 Citations1998Sabine Yerly
Levels of HIV-1 RNA and CD4+ cell counts provided independent and complementary information on clinical outcomes and the RNA/CD4+ ratio was the best single predictor.
The Journal of Infectious DiseasesCell‐Associated HIV‐1 RNA in Blood as Indicator of Virus Load in Lymph Nodes
38 Citations1999Sabine Yerly, O. T. Rutschmann +5 more
Regression analysis shows that, in treated patients with sustained low viremia, cell-associated RNA and DNA in blood are better predictors of virus load in LNs than vireia.